Myrtenal averts apoptotic evasion of cancer cells in 7,12-dimethylbenz(a)anthracene induced experimental oral carcinogenesis

Buddhan R\textsuperscript{1}, Manoharan S\textsuperscript{*1}, Muralinaidu R\textsuperscript{2}

\textsuperscript{1}Department of Biochemistry and Biotechnology, Annamalai University, Annamalainagar, Tamil Nadu, India
\textsuperscript{2}Department of Oral Pathology, Rajah Muthiah Dental College, Annamalai University, Annamalainagar, Tamil Nadu, India

\textbf{Article History:}

Received on: 01 Jan 2020
Revised on: 28 Jan 2020
Accepted on: 01 Feb 2020

\textbf{Keywords:}

Myrtenal, oral cancer, apoptosis

\textbf{ABSTRACT}

Apoptotic avoidance is one of the foremost characteristic features of tumour cells. Apoptotic induction in cancer cells could thus help to identify new anticancer agents from the natural products. The present study has taken an effort to investigate the apoptotic efficacy of myrtenal, a monoterpene, in 7,12-dimethylbenz(a)anthracene (DMBA) induced oral carcinoma in male golden Syrian hamsters. The present study used the potent carcinogen, 7,12-dimethylbenz(a)anthracene, to develop oral tumours in the buccal pouches of the golden Syrian hamsters. Topical application of the above said carcinogen on the buccal mucosa (3 times a week for 14 weeks) resulted in well differentiated oral squamous cell carcinoma. The apoptotic potential of myrtenal was investigated using a spectrum of apoptotic markers, including pro-apoptotic and anti-apoptotic markers. Oral tumours developed in the buccal mucosa of hamsters showed higher expression of mutant p\textsuperscript{53} protein, Bcl-2 and lowered expression of Bax, Bad, Bid, caspase 3 and caspase 9. Myrtenal treatment at a dose of 230mg/kg bw orally to the hamsters treated with DMBA modulated the above said apoptotic markers towards tumour suppression or inhibition. The present findings thus suggests that the tumour preventive effect of myrtenal could partly be ascribed to its apoptotic induction potential during DMBA induced oral carcinogenesis.

*Corresponding Author

Name: Manoharan S
Phone: +91 94425 48117
Email: sakshiman@rediffmail.com

ISSN: 0975-7538
DOI: https://doi.org/10.26452/ijrps.v11i3.2359

\textbf{INTRODUCTION}

Human body is endowed with a well balanced homeostatic mechanism to remove the unwanted or damaged cells arised through various cellular processes (Lee \textit{et al.}, 2018). Any defect in mitosis or removal of damaged cells could result in various illness especially cancer (Iyama and Wilson, 2013). The apoptotic process is an important phenomenon of multicellular organisms to maintain the tissue homeostasis and to control the proliferation of cells (Chen \textit{et al.}, 2018). Apoptosis, a cell suicide, is regulated by a series of regulatory genes and of which some genes play a role in the apoptotic initiation, while the others are involved in the apoptotic inhibition (Goldar \textit{et al.}, 2015). The family of apoptotic proteins is comprised of pro-apoptotic and anti-apoptotic proteins. Any disturbances in the ratio of pro- and anti-apoptotic proteins in the cell could lead to abnormal proliferation of cells (Jan R and Chaudhry G E, 2019; Pistritto \textit{et al.}, 2016). The apoptotic proteins expression could also help
to assess the prognosis of cancer (Hassan et al., 2014). It has been clearly pointed out that any defect or imbalance in intrinsic or extrinsic pathway of apoptosis could lead to carcinogenesis (Belkacemi, 2018). Altered status of pro-apoptotic and anti-apoptotic proteins have been explored in oral carcinogenesis. As apoptotic dys-regulation has massive impact on cell proliferation and cell cycle regulation, researchers target apoptotic markers to study the anticancer efficacy of natural products and their bioactive entities (Pfeffer and Singh, 2018).

Myrtenal, in recent years, attracted the attention of several researchers due to its multiple biochemical and pharmacological efficacies such as anti-inflammatory (Dragomanova et al., 2019; Rathinam et al., 2019), neuroprotective (Kaufmann et al., 2011), antioxidant (Lokeshkumar et al., 2015; Dragomanova et al., 2018), anti-diabetic (Pari and Rathinam, 2016), antihyperlipidemic (Pari and Rathinam, 2016) and anticancer (Lokeshkumar et al., 2015) properties. Myrtenal has been shown to have protective effect against liver disorders (Lin gaiah et al., 2013), diabetes (Babu et al., 2012; Rathinam et al., 2019). A very few studies have also reported its cytotoxic potential against tumour cell lines (Suslov et al., 2015; Martins et al., 2019). The present study assesses the apoptotic induction potential of myrtenal in 7,12-dimethylbenz(a)anthracene induced oral carcinogenesis.

MATERIALS AND METHODS

For the present study, thirty male golden Syrian hamsters (8-10 weeks old; 80—120g) were procured from National Institute of Nutrition, Hyderabad. The hamsters were then grouped into five categories and maintained in the well-sophisticated Central Animal House, Annamalai University, according to the ethics principles of Institutional ethics committees (Committee no.160/1999/CPCSEA, 25/11/1999, Proposal No.1175). All the animals received their diet and water ad libitum. The experimental protocol is represented in the Figure 1.

TUMOUR INDUCTION

The present study used the potent carcinogen, 7,12-dimethylbenz(a)anthracene, to develop oral tumours in the buccal pouches of the golden Syrian hamsters. Topical application of the above said carcinogen on the buccal mucosa (3 times a week for 14 weeks) resulted in well differentiated oral squamous cell carcinoma.

IMMUNOHISTOCHEMISTRY

Immuno-histochemical analysis was employed to analyse the expression pattern of apoptotic markers in the buccal mucosa of control and experimental animals. Paraffin embedded tissue sections were incubated with the corresponding primary monoclonal antibodies to the apoptotic markers (p53, Bax, Bid, Bad, caspase 3 and 9) after the retrieval of the antigens and routine procedure (Whiteside and Munglani, 1998). The slides were then treated with the horse radish peroxidase labelled secondary antibodies. The slides were subsequently incubated with the chromogen, Diaminobenzidine (DAB). The slides were than counterstained with haematoxylin. The immuno-expression pattern of the apoptotic markers were examined under microscope, after attaining the desirable colour intensity.

RESULTS AND DISCUSSION

The immunoexpression pattern of buccal mucosa apoptotic markers (pro-apoptotic and antiapoptotic) in control and experimental animals were represented in Figures 2, 3, 4, 5, 6, 7 and 8. The immunoexpression pattern of p53 (mutant) and Bcl-2 was found to be overexpressed in tumour bearing hamsters (group 2) as compared to control hamsters (group 1). On the other hand, the expression pattern of Bax, Bid, Bad, caspase 3 and 9 was found to be significantly decreased in hamsters treated with DMBA alone. Myrtenal administration downregulated the expression of mutant p53 and Bcl-2 and enhanced the expression of Bax, Bid, Bad, caspase 3 and 9 in the DMBA treated hamsters (chemopreventive phase) and significantly improved the expression pattern in the chemotherapeutic phase as well (DMBA→myrtenal treated hamsters; group 4). The immunoexpression pattern of the above said apoptotic markers in hamsters treated with myrtenal alone (group 5) was much comparable to that of con-
Figure 2: p53 expression in the buccal mucosa of experimental hamsters

A- Tissues from control hamsters showed no p53 expression in the basal and parabasal cells.
B- Tissues from DMBA alone treated hamsters showed higher mutant p53 expression in the keratin pearls surrounded by dysplastic epithelial cells.
C- Tissues from DMBA + myrtenal treated hamsters showed very minimal p53 expression in the basal cells.
D- Tissues from DMBA → myrtenal treated hamsters showed minimal p53 expression in the basal cells.
E- Tissues from myrtenal alone treated hamsters showed no p53 expression in the basal and parabasal cells.

Figure 3 shows that
A- Tissues from control hamsters showed no Bcl-2 expression in the epithelium.
B- Tissues from DMBA alone treated hamsters dysplastic epithelium island are showed Bcl-2 overexpression.

E
Figure 4: Bax expression in the buccal mucosa of experimental hamsters

A- Tissues from control hamsters showed Bax expression in the basal cells throughout the epithelial layer.
B- Tissues from DMBA alone treated hamsters showed no Bax expression.
C- Tissues from DMBA + myrtenal treated hamsters showed minimal expression of Bax in the basal cells.
D- Tissues from DMBA → myrtenal treated hamsters showed very minimal expression of Bax in the basal cells.
E- Tissues from myrtenal alone treated hamsters showed Bax expression in the basal cells.

Figure 5 shows that

A- Tissues from control hamsters showed Bax expression in the basal cells throughout the epithelial layer.
B- Tissues from DMBA alone treated hamsters showed no Bcl-2 expression.
C- Tissues from DMBA + myrtenal treated hamsters showed minimal expression of Bcl-2 in both basal and parabasal cells.
D- Tissues from DMBA → myrtenal treated hamsters showed no expression of Bcl-2 in both basal and parabasal cells.
E- Tissues from myrtenal alone treated hamsters showed no expression of Bcl-2 in both basal and parabasal cells.
Figure 6: Bad expression in the buccal mucosa of experimental hamsters

A- Tissues from control hamsters showed expression of Bid throughout the epithelial layer.
B- Tissues from DMBA alone treated hamsters showed no Bid expression detectable.
C- Tissues from DMBA + myrtenal hamsters showed Bid expression throughout basal and parabasal cells.
D- Tissues from DMBA → myrtenal treated hamsters showed moderate Bid expression.
E- Tissues from myrtenal alone treated hamsters showed Bid expression throughout the epithelial layer.

Figure 7: Caspase-3 expression in the buccal mucosa of experimental hamsters

A- Tissues from control hamsters showed Bad expression throughout the epithelial layer.
B- Tissues from DMBA alone treated hamsters showed no Bad expression.
C- Tissues from DMBA + myrtenal treated hamsters showed expression of Bad throughout the epithelial layer.
D- Tissues from DMBA → myrtenal treated hamsters showed minimal expression of Bad in the basal and parabasal cells.

Figure 6 shows that...
E- Tissues from myrtenal alone treated hamsters showed Bad expression in throughout the epithelial layer.

Figure 7 shows that
A- Tissues from control hamsters showed expression of caspase-3 in the basal cells.
B- Tissues from DMBA alone treated hamsters showed no caspase-3 expression.
C- Tissues from DMBA + myrtenal treated hamsters showed expression of caspase-3 in the basal cells.
D- Tissues from DMBA → myrtenal treated hamsters showed minimal expression of caspase-3 in the basal and parabasal cells.
E- Tissues from myrtenal alone treated hamsters showed expression of caspase-3 in both basal and parabasal cells of epithelium.

Figure 8 shows that
A- Tissues from control hamsters showed caspase-9 expression in the basal cells.
B- Tissues from DMBA alone hamsters showed no caspase-9 expression.
C- Tissues from DMBA + Myrtenal treated hamsters showed expression of caspase-9 in the basal cells of the epithelial layer.
D- Tissues from DMBA → Myrtenal treated hamsters showed very minimal expression of caspase-9 in the basal and parabasal cells of epithelium.
E- Tissues from Myrtenal alone treated hamsters showed expression of caspase-9 in the basal cells.

Apoptotic machinery is a complex cascade, which contains several signaling pathways to maintain the integrity of the genome (Hassan et al., 2014). Apoptotic process causes diverse morphological alterations in the cell structure accompanied by a series of biochemical events, which together in turn clear the apoptotic cells from the body. The major morphological alterations that occur in the apoptotic cells include nuclear condensation, DNA fragmentation, blebbing of cell membrane and shrinkage of cells (D’arcy, 2019). The growth of cancer cells is mainly due to their ability to evade from the apoptotic cascade (Wong, 2011). Evasion of apoptosis could thus result in transcriptional and translational defects, which in turn lead to abnormal cell proliferation. p53, a well known tumour suppressor gene, plays a vital and critical role in the regulation of cell cycle, DNA repair and in programmed cell death (Ozaki and Nakagawara, 2011). p53 is a nuclear phosphoprotein and is activated in the cell by both exogenous and endogenous stress stimuli. While normal wild type p53 has a very short life span, the mutant p53 has extended half-life due to its stability (Ozaki and Nakagawara, 2011).

p53 has been documented as the major target of several carcinogens to induce genetic alterations to cause abnormal cell proliferation. Immunohistochemical analysis of p53 expression always explored the higher expression of mutant p53 protein, as the wild type p53 protein cannot be measured due to its short half life. p53 expression should be enhanced in the tumour cells in order to provide effective therapy to eradicate the tumour cells (Parrales and
Bcl-2 and suppressed Bax expression in human oral tumour cells (between the immunoexpression of Bax and Bcl-2 cinogenesis have explored an inverse relationship shown in several cancers including colorectal and et al. ing their death rather than inhibiting apoptosis (et al. et al.). Bcl-2 overexpression support the switch to decide the fate of the cell survival or death. Bcl-2 family proteins is comprised of both pro-apoptotic and anti-apoptotic proteins. While anti-apoptotic proteins suppress apoptosis by inhibiting the release of mitochondrial cytochrome C, the pro-apoptotic proteins promote the release of cytochrome C to the initiate apoptotic cell death (Wang and Youle, 2009). Bcl-2 family proteins play prominent role in the cell cycle and apoptotic pathway. Bcl-2, is involved in the process of apoptotic inhibition by means of inactivating caspases and by preventing translocation of cytochrome C. Overexpression of Bcl-2 has been shown in oral pre-neoplastic conditions such as dysplasia (Wong, 2011). (Arumugam et al., 2017) reported that Bcl-2 overexpression occurs in parallel with tumour progression. (Pavithra et al., 2017) have shown 33% of oral cancer cases showed positive Bcl-2 expression. It has been reported that the status of Bcl-2 family protein can be used as prognostic indicator of oral carcinoma. A positive correlation between tumour recurrence and Bcl-2 expression pattern has been documented well in various cancers including breast and oral carcinoma (Alam et al., 2018). Bcl-2 overexpression support the abnormal proliferation of tumour cells by suppressing their death rather than inhibiting apoptosis (Selvasundaram et al., 2018). Bax mutation has been shown in several cancers including colorectal and oral carcinoma (Rios et al., 2015; Selvasundaram et al., 2018). Profound experimental and human carcinogenesis have explored an inverse relationship between the immunoexpression of Bax and Bcl-2 in tumour cells (Frenzel et al., 2009). (Thomas and Sethupathy, 2015) have shown overexpression of Bcl-2 and suppressed Bax expression in human oral squamous cell carcinoma. BH3- interacting domain death antagonist (Bid) serves as a pro-apoptotic Bcl-2 family member and play a vital role in programmed cell death. Bid expression has been shown to sensitize the tumour cells for the chemotherapeutic effect of the anticancer agents (Ye et al., 2019). Bad a pro-apoptotic protein stimulates apoptosis by inhibiting or blocking the activation of bcI-2. It has been reported that Bid activated the Bax in mediating apoptosis by binding with Bcl-2 family proteins. Bid has a crucial role in repairing the DNA damaged cells via programmed cell death. Impairment in Bad (Bcl-2 antagonist of cell death) expression play a crucial role in the carcinogenic process. Bad binds to anti-apoptotic proteins of Bcl-2 family and regulates the process of apoptosis. Caspases are the most important apoptotic signalling molecules, which are categorized as initiator caspases and executioner caspases depending on their mechanism of action. While caspase 8 and 9 are involved in apoptotic initiation, caspases 3,6 and 7 serves as executioner caspases to complete the programmed cell death (Parrish et al., 2013). Activation of caspases and externalization of phosphatidyl serine are the frequent mechanisms found during the apoptotic process (Zhang et al., 2018). As caspases have vital role in the inhibition of apoptosis, caspase activation has been utilized as a target to search for new anticancer agents. (Huang et al., 2017) suggested that caspase 3 expression in the tumour tissues can be used as a prognostic indicator for assessing the particular stage of the oral squamous cell carcinoma. Using immunohistochemistry, abnormal caspase 3 expression has been reported in oral tumour tissues as compared to their adjacent normal tissues. Almost all types of malignancy showed abnormal expression of caspase 3 (Hu et al., 2014). Profound studies showed a positive association between higher caspase 3 expression and tumour size, tumour staging and lymphnode metastasis (Huang et al., 2017). An association between caspase 3 expression and oral cancer prognosis has also been reported (Liu et al., 2017). Overexpression of caspase 3 in oral carcinoma might be due to enhance or promote the apoptotic cascade. (Veeravarmal et al., 2016) reported low or absence of caspase 3 expression in oral squamous cell carcinoma. They suggested that caspase 3 expression tends to be decreased as the tumour progress. Low expression of caspase 3 in oral tumour tissues was also reported by (Li et al., 2017). An impairment in the status of caspase 3 and 9 has been reported frequently in cancer and its progression (Bernard et al., 2019). (Fong, 2006) have shown the down regula-
tion of caspases in tumourigenesis.

Myrtenal, a monoterpene, plays a vital role in the inhibition or prevention of several disorders. (Babu et al., 2012) pointed out that myrtenal suppressed the liver tumour formation in Wistar rats via down-regulating the antiapoptotic (Bcl-2) protein and upregulating pro-apoptotic (Bax) proteins. It has also been reported that myrtenal has the potent ability to up-regulate the expression of p^53^, a pro-apoptotic and a tumour suppressive gene, in experimental hepatocarcinogenesis (Lingaiah et al., 2013). In the present study, defect in pro-apoptotic and anti-apoptotic markers expression pattern was demonstrated in oral carcinogenesis using immunohistochemical studies. Administration of myrtenal to DMBA treated animals in the chemopreventive and chemotherapeutic phase modulated the immunoexpression pattern of both pro-apoptotic and anti-apoptotic proteins towards the inhibition of tumour formation (chemopreventive phase; group 3) and suppressed or reduced the size and burden of the tumours in the chemotherapeutic phase (group IV). The observed findings thus suggest that myrtenal might have exerted anticancer property via its pro-apoptotic potential during DMBA induced oral carcinogenesis.

**CONCLUSIONS**

The present study, for the first time, scientifically validated and explored the chemopreventive and chemotherapeutic potential of myrtenal in DMBA induced oral carcinogenesis by utilizing the expression pattern of apoptotic markers as a molecular end point during DMBA induced oral carcinogenesis. The results of the present study revealed a potent pro-apoptotic efficacy of myrtenal in DMBA induced oral carcinogenesis. Thus, the present study concludes that myrtenal could be considered as a promising candidate for the prevention and treatment of oral cancer.

**ACKNOWLEDGEMENTS**

Financial support from ICMR, New Delhi to Mr.R.Buddhan in the form of Senior Research Fellowship is gratefully acknowledged. The authors extend their sincere thanks to UGC-SAP and DST-FIST for providing infrastructural and instrumental facilities to carry out this research work.

**Conflict of Interest**

None.

**Funding Support**

None.
tial expression study. *Journal of Clinical Pathology*, 59(2):179–183.

Frenzel, A., Grespi, F., Chmelewskij, W., Villunger, A. 2009. Bcl2 family proteins in carcinogenesis and the treatment of cancer. *Apoptosis*, 14(4):584–596.

Goldar, S., Khaniani, M. S., Derakhshan, S. M., Baradaran, B. 2015. Molecular Mechanisms of Apoptosis and Roles in Cancer Development and Treatment. *Asian Pacific Journal of Cancer Prevention*, 16(6):2129–2144.

Hassan, M., Watari, H., Abualmaaty, A., Ohba, Y., Sakuragi, N. 2014. Apoptosis and Molecular Targeting Therapy in Cancer. *BioMed Research International*, pages 1–23.

Hu, Q., Peng, J., Liu, W., He, X., Cui, L., Chen, X., Yang, M., Liu, H., Liu, S., Wang, H. 2014. Elevated cleaved caspase-3 is associated with shortened overall survival in several cancer types. *International Journal of Clinical and Experimental Pathology*, 7(8):5057–5070.

Huang, J. S., Yang, C. M., Wang, J. S., Liou, H. H., Hsieh, I. C., Li, G. C., Liu, P. F. 2017. Caspase-3 expression in tumourtumourigenesis and prognosis of buccal mucosa squamous cell carcinoma. *Oncotarget*, 8(48):84237–84247.

Iyama, T., Wilson, D. M. 2013. DNA repair mechanisms in dividing and non-dividing cells. *DNA Repair*, 12(8):620–636.

Jan R and Chaudhry G E 2019. Understanding apoptosis and apoptotic pathways targeted cancer therapeutics. *Adv Pharm Bull*, 9(2):205–218.

Kaufmann, D., Dogra, A. K., Wink, M. 2011. Myrtenal inhibits acetylcholinesterase, a known Alzheimer target. *Journal of Pharmacy and Pharmacology*, 63(10):1368–1371.

Khanna, S., Atul, K., Vidyarthi, U., Singh, Umesh, C., Singh, R. K. 2012. Expression of p53 protein in oral leukoplasia and squamous cell carcinoma. *World Journal of Surgical Medical and Radiation Oncology*, 8(1):78–82.

Lee, S. Y., Ju, M. K., Jeon, H. M., Jeong, E. K., Lee, Y. J., Kim, C. H., Kang, H. S. 2018. Regulation of Tumour Progression by Programmed Necrosis. *Oxidative Medicine and Cellular Longevity*, pages 1–28.

Li, S., Yang, Y., Ding, Y., Tang, X., Sun, Z. 2017. Impacts of survivin and caspase-3 on apoptosis and angiogenesis in oral cancer. *Oncology Letters*, 14(3):3774–3779.

Lingaiah, H. B., Natarajan, N., Thamaraiselvan, R., Srinivasan, P., Periyasamy, B. M. 2013. Myrtenal ameliorates diethylnitrosamine-induced hepatocarcinogenesis through the activation of tumour suppressor protein p53 and regulation of lysosomal and mitochondrial enzymes. *Fundamental & Clinical Pharmacology*, 27(4):443–454.

Liu, P. F., Hu, Y. C., Kang, B. H., Tseng, Y. K., Wu, P. C., Liang, C. C., Shu, C. W. 2017. Expression levels of cleaved caspase-3 and caspase-3 in tumourtumourigenesis and prognosis of oral tongue squamous cell carcinoma. *PLOS ONE*, 12(7).

Lokeshkumar, B., Sathishkumar, V., Nandakumar, N., Rengarajan, T., Madankumar, A., Balasubramanian, M. P. 2015. Anti-Oxidative Effect of Myrtenal in Prevention and Treatment of Colon Cancer Induced by 1, 2-Dimethyl Hydrazine (DMH) in Experimental Animals. *Biomolecules & Therapeutics*, 23(5):471–478.

Manoharan, S., Rajasekaran, D., Prabhakar, M., Karthikeyan, S., Manimaran, A. 2015. Modulating effect of Enicostemma littorale on the expression pattern of apoptotic, cell proliferative, inflammatory and angiogenic markers During 7, 12-Dimethylbenz (a) anthracene induced hamster buccal pouch carcinogenesis. *Toxicology International*, 22(1):130–140.

Martins, B. X., Arruda, R. F., Costa, G. A., Jerdy, H., Souza, S. B. D., Santos, J. M., Façanha, A. R. 2019. Myrtenal-induced V-ATPase inhibition - A toxicity mechanism behind tumortumour cell death and suppressed migration and invasion in melanoma. *Biochimica et Biophysica Acta (BBA) - General Subjects*, 1863(1):1–12.

Mohite, D., Hande, A., Gupta, R., Chaudhary, M., Mohite, P., Patil, S., Gawande, M. 2018. Immuno-histochemical evaluation of expression pattern of p53, p63, and p73 in epithelial dysplasia. *Journal of Datta Meghe Institute of Medical Sciences University*, 13(3):122–131.

Ozaki, T., Nakagawara, A. 2011. Role of p53 in Cell Death and Human Cancers. *Cancers*, 3(1):994–1013.

Pari, L., Rathinam, A. 2016. Anti-diabetic effect of myrtenal on plasma and tissue glycoproteins components in stz induced experimental diabetic rats. *Journal of Diseases and Medicinal Plants*, 2(1):11–16.

Parrales, A., Iwakuma, T. 2015. Targeting Oncogenic Mutant p53 for Cancer Therapy. *Frontiers in Oncology*, 5(288).

Parrish, A. B., Freel, C. D., Kornbluth, S. 2013. Cellular Mechanisms Controlling Caspase Activation and Function. *Cold Spring Harbor Perspectives in Biology*, 5:8672–008672.
cell carcinomas: Markers of significance in future diagnostics and possibly therapeutics. *Journal of Oral and Maxillofacial Pathology*, 20(3):384–393.

Pavithra, V., Kumari, K., Haragannavar, V. C., Rao, R. S., Nambiar, S., Augustine, D., ., S. S. 2017. Possible role of bcl-2 expression in metastatic and non metastatic oral squamous cell carcinoma. *J Clin Diagn Res*, 11(9):51–54.

Pfeffer, C. M., Singh, A. T. K. 2018. Apoptosis: A Target for Anticancer Therapy. *International Journal of Molecular Sciences*, 19(2):448–448.

Pistritto, G., Trisciuglio, D., Ceci, C., Garufi, A., Orazi, G. 2016. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. *Aging*, 8(4):603–619.

Rathinam, A., Pari, L., Venkatesan, M., Munusamy, S. 2019. Myrtenal attenuates oxidative stress and inflammation in a rat model of streptozotocin-induced diabetes. *Archives of Physiology and Biochemistry*, pages 1–9.

Rios, A., Rodríguez, J. M., Carbonel, P., ., P. P. 2015. BAX as a susceptibility factor in hereditary non polyposis colorectal cancer. *Rev Esp Enferm Dig*, 107(8):520–521.

Selvasundaram, R., Shanmugam, M., Naidu, R., Vasudevan, K., Elanchezhiyan, C., Muthulingam, M. 2018. Effect of esculetin on the expression pattern of apoptotic markers in experimental oral carcinogenesis. *International Journal of Research in Pharmaceutical Sciences*, 9(2):255–262.

Suslov, E., Ponomarev, K., Rogachev, A., Pokrovsky, M., Pokrovsky, A., Pykhtina, M., Salakhutdinov, N. 2015. *Compounds Combining Aminoadamantane and Monoterpene Moieties: Cytotoxicity and Mutagenic Effects*, 11:629–635.

Thomas, S. A., Sethupathy, S. 2015. Evaluation of oxidative stress in patients with Oral Squamous Cell Carcinoma. *International Journal of Pharma and Bio Sciences*, 6(1):289–293.

Veeravarmal, V., Austin, R. D., Siddavaram, N., Thiruneelakandan, S., ., N. M. 2016. Caspase-3 expression in normal oral epithelium, oral submucous fibrosis and oral squamous cell carcinoma. *J Oral Maxillofac Pathol*, 20(3):445–452.

Wong, R. S. Y. 2011. Apoptosis in cancer: from pathogenesis to treatment. *Journal of Experimental & Clinical Cancer Research*, 30(1).

Ye, Q., Liu, K., Shen, Q., Li, Q., Hao, J., Han, F., Jiang, R. W. 2019. Reversal of Multidrug Resistance in Cancer by Multi-Functional Flavonoids. *Frontiers in Oncology*, 9:487–487.

Zhang, Y., Chen, X., Gueydan, C., Han, J. 2018. Plasma membrane changes during programmed cell deaths. *Cell Research*, 28(1):9–21.